Symptomatic therapy and rehabilitation in primary progressive multiple sclerosis
- PMID: 22013521
- PMCID: PMC3196037
- DOI: 10.1155/2011/740505
Symptomatic therapy and rehabilitation in primary progressive multiple sclerosis
Abstract
Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the central nervous system and a major cause of chronic neurological disability in young adults. Primary progressive MS (PPMS) constitutes about 10% of cases, and is characterized by a steady decline in function with no acute attacks. The rate of deterioration from disease onset is more rapid than relapsing remitting and secondary progressive MS types. Multiple system involvement at onset and rapid early progression have a worse prognosis. PPMS can cause significant disability and impact on quality of life. Recent studies are biased in favour of relapsing remitting patients as treatment is now available for them and they are more likely to be seen at MS clinics. Since prognosis for PPMS is worse than other types of MS, the focus of rehabilitation is on managing disability and enhancing participation, and application of a "neuropalliative" approach as the disease progresses. This chapter presents the symptomatic treatment and rehabilitation for persons with MS, including PPMS. A multidisciplinary approach optimizes the intermediate and long-term medical, psychological and social outcomes in this population. Restoration and maintenance of functional independence and societal reintegration, and issues relating to quality of life are addressed in rehabilitation processes.
Figures










Similar articles
-
Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis.Mult Scler. 2013 Feb;19(2):188-98. doi: 10.1177/1352458512451510. Epub 2012 Jun 26. Mult Scler. 2013. PMID: 22736750 Free PMC article.
-
Societal costs of primary progressive multiple sclerosis in Australia and the economic impact of a hypothetical disease-modifying treatment that could delay disease progression.J Med Econ. 2021 Jan-Dec;24(1):140-149. doi: 10.1080/13696998.2021.1872585. J Med Econ. 2021. PMID: 33461357
-
Mitoxantrone: a review of its use in multiple sclerosis.CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review.
-
A comparison of serum inflammatory parameters in progressive forms of multiple sclerosis.Mult Scler Relat Disord. 2023 Nov;79:105004. doi: 10.1016/j.msard.2023.105004. Epub 2023 Sep 11. Mult Scler Relat Disord. 2023. PMID: 37738756
-
Ocrelizumab: A Review in Multiple Sclerosis.Drugs. 2022 Feb;82(3):323-334. doi: 10.1007/s40265-022-01672-9. Epub 2022 Feb 22. Drugs. 2022. PMID: 35192158 Free PMC article. Review.
Cited by
-
Cognitive-motor dual-task training improves dynamic stability during straight and curved gait in patients with multiple sclerosis: a randomized controlled trial.Eur J Phys Rehabil Med. 2024 Feb;60(1):27-36. doi: 10.23736/S1973-9087.23.08156-X. Epub 2023 Nov 23. Eur J Phys Rehabil Med. 2024. PMID: 37997324 Free PMC article. Clinical Trial.
-
The "Surprise Question" in Neurorehabilitation-Prognosis Estimation by Neurologist and Palliative Care Physician; a Longitudinal, Prospective, Observational Study.Front Neurol. 2018 Sep 24;9:792. doi: 10.3389/fneur.2018.00792. eCollection 2018. Front Neurol. 2018. PMID: 30319526 Free PMC article.
-
Music-based therapy in rehabilitation of people with multiple sclerosis: a systematic review of clinical trials.Arq Neuropsiquiatr. 2021 Jun;79(6):527-535. doi: 10.1590/0004-282X-ANP-2020-0374. Arq Neuropsiquiatr. 2021. PMID: 34320057 Free PMC article.
-
Rehabilitation for people with multiple sclerosis: an overview of Cochrane Reviews.Cochrane Database Syst Rev. 2019 Jan 14;1(1):CD012732. doi: 10.1002/14651858.CD012732.pub2. Cochrane Database Syst Rev. 2019. PMID: 30637728 Free PMC article.
-
Management of fatigue in persons with multiple sclerosis.Front Neurol. 2014 Sep 15;5:177. doi: 10.3389/fneur.2014.00177. eCollection 2014. Front Neurol. 2014. PMID: 25309504 Free PMC article. Review.
References
-
- Programme for Neurological Diseases and Neurosciences Department of Mental Health and Substance Abuse. Atlas: Country Resources for Neurological Disorders: Results of a Collaborative Study of World Health Organization and World Federation of Neurology. Geneva, Switzerland: World Health Organization; 2004.
-
- Torkildsen NG, Lie SA, Aarseth JH, Myhr KM. Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway. Multiple Sclerosis. 2008;14(9):1191–1198. - PubMed
-
- Khan F, McPhail T, Brand C, Turner-Stokes L, Kilpatrick T. Disability profile and quality of life in multiple sclerosis in an Australian community cohort. International Journal of Rehabilitation Research. 2006;29(2):87–96. - PubMed
-
- Rovaris R, Judica E, Sastre-Garriga J, et al. Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. Multiple Sclerosis. 2008;14(4):455–466. - PubMed
-
- Montalban X. Primary progressive multiple sclerosis. Current Opinion in Neurology. 2005;18(3):261–266. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources